Andrea Lauren Christman Schneider

Andrea Lauren Christman Schneider

Auto-generated profile, based on publicly available information

Andrea Lauren Christman Schneider

University of Pennsylvania Perelman School of Medicine

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2017 in JAMA
Verified
Journal Article
Open access
PDF file
RGRebecca F. Gottesman
Rebecca F. Gottesman
ASAndrea L. C. Schneider
Andrea L. C. Schneider
YZYun Zhou
Yun Zhou
JCJosef Coresh
Josef Coresh
EGEdward Green
Edward Green
TMTom Mosley
Tom Mosley
Increasing evidence supports a role of vascular risk factors and markers in the development and etiology of Alzheimer disease (AD). Most major vascular risk factors, including hypertension,1-4 diabetes,5 smoking,3,6 and hypercholesterolemia,4,7 particularly when measured in midlife, have been associated with risk of dementia generally and AD specifically. Whether these risk factors directly increase the neurodegeneration specifically associated with AD (such as through increasing amyloid deposition) or lead to other cerebral changes that, in conjunction with ongoing neurodegeneration, might worsen cognitive performance is not yet known.

16 July 2014 in JAMA
Verified
Journal Article
Open access
PDF file
SKSilvia Koton
Silvia Koton
ASAndrea L. C. Schneider
Andrea L. C. Schneider
WRWayne D. Rosamond
Wayne D. Rosamond
ESEyal Shahar
Eyal Shahar
YSYingying Sang
Yingying Sang
JCJosef Coresh
Josef Coresh
Stroke ranks fourth among all causes of death in the United States1 and is recognized as a leading cause of serious physical and cognitive long-term disability in adults.2 Almost 800 000 US residents experience an incident or recurrent stroke each year, and more than 600 000 of these are first-ever events.3 Stroke incidence varies by sex and ethnic group.4-6

1 October 2014 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
RGRebecca F. Gottesman
Rebecca F. Gottesman
ASAndrea L. C. Schneider
Andrea L. C. Schneider
MAMarilyn Albert
Marilyn Albert
AAAlvaro Alonso
Alvaro Alonso
KBKaren Bandeen-Roche
Karen Bandeen-Roche
TMThomas H. Mosley
Thomas H. Mosley
Quiz Ref ID Accumulating evidence suggests that hypertension is an important risk factor for cognitive change and dementia. Midlife (45-55 years of age) hypertension may be a stronger risk factor than late-life hypertension, as demonstrated in the Honolulu-Asia Aging Study (midlife blood pressure [BP] was associated with dementia1,2 and late-life cognitive function3) and in a Finnish cohort (for dementia4 and cognitive performance5). In the Atherosclerosis Risk in Communities (ARIC) Study, hypertension was more strongly associated with hospitalizations with a discharge code for dementia when defined in midlife vs late life.6 Other studies7-14 showed hypertension, especially in midlife, predicted cognitive decline in certain cognitive domains, but these studies had a short follow-up, examined a primarily white population, did not address the role of antihypertensives, or did not address attrition.

2 December 2014 in Annals of Internal Medicine
Verified
Journal Article
Closed access
ARAndreea M. Rawlings
Andreea M. Rawlings
ASA. Richey Sharrett
A. Richey Sharrett
ASAndrea L.C. Schneider
Andrea L.C. Schneider
JCJosef Coresh
Josef Coresh
MAMarilyn Albert
Marilyn Albert
ESElizabeth Selvin
Elizabeth Selvin
Type 2 diabetes is associated with dementia risk, but whether diabetes and prediabetes are associated with cognitive decline is unclear. In this prospective cohort study, the authors sought to dete... Background: Type 2 diabetes is associated with dementia risk, but evidence is limited for possible associations of diabetes and prediabetes with cognitive decline. Objective: To determine whether d...

20 February 2014 in Journal of the International Neuropsychological Society
Verified
Journal Article
Closed access
PDF file
PPPriya Palta
Priya Palta
ASAndrea L.C. Schneider
Andrea L.C. Schneider
GBGeert Jan Biessels
Geert Jan Biessels
PTPegah Touradji
Pegah Touradji
FHFelicia Hill-Briggs
Felicia Hill-Briggs
The objectives were to conduct a meta-analysis in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards to determine effect sizes (Cohen's d) for cognitive dysfunction in adults with type 2 diabetes, relative to nondiabetic controls, and to obtain effect sizes for the most commonly reported neuropsychological tests within domains. Twenty-four studies, totaling 26,137 patients (n = 3351 with diabetes), met study inclusion criteria. Small to moderate effect sizes were obtained for five of six domains: motor function (3 studies, n = 2374; d = −0.36), executive function (12 studies, n = 1784; d = −0.33), processing speed (16 studies, n = 3076; d = −0.33), verbal memory (15 studies, n = 4,608; d = −0.28), and visual memory (6 studies, n = 1754; d = −0.26). Effect size was smallest for attention/concentration (14 studies, n = 23,143; d = −0.19). The following tests demonstrated the most notable performance decrements in diabetes samples: Grooved Pegboard (dominant hand) (d = −0.60), Rey Auditory Verbal Learning Test (immediate) (d = −0.40), Trails B (d = −0.39), Rey-Osterreith Complex Figure (delayed) (d = −0.38), Trails A (d = −0.34), and Stroop Part I (d = −0.28). This study provides effect sizes to power future epidemiological and clinical diabetes research studies examining cognitive function and to help inform the selection of neuropsychological tests. (JINS, 2014, 20, 1–14)

4 January 2016 in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Verified
Journal Article
Open access
DKDavid S. Knopman
David S. Knopman
RGRebecca F. Gottesman
Rebecca F. Gottesman
ASAlbert Richey Sharrett
Albert Richey Sharrett
LWLisa M. Wruck
Lisa M. Wruck
BWBeverly Gwen Windham
Beverly Gwen Windham
TMThomas H. Mosley
Thomas H. Mosley
Introduction: We examined prevalence of mild cognitive impairment (MCI) and dementia in the Atherosclerosis Risk in Communities (ARIC) Neurocognitive study.Methods: Beginning in June, 2011, we invited all surviving ARIC participants to undergo cognitive, neurologic, and brain imaging assessments to diagnose MCI or dementia and assign an etiology for the cognitive disorder.Results: Of 10,713 surviving ARIC participants (age range, 69–88 years), we ascertained cognitive diagnoses in 6471 in person, 1966 by telephone interviews (participant or informant), and the remainder by medical record review. The prevalence of dementia was 9.0% and MCI 21%. Alzheimer's disease (AD) was the primary or secondary etiology in 76% of dementia and 75% of MCI participants. Cerebrovascular disease was the primary or secondary etiology in 46% of dementia and 32% of MCI participants.Discussion: MCI and dementia were common among survivors from the original ARIC cohort. Nearly 30% of the ARIC cohort received diagnoses of either dementia or MCI, and for the majority of these individuals, the etiologic basis was attributed to AD.